Genetron Health and NeoGenomics reached a strategic cooperation to help global oncology drug research and development

Beijing, November 8, 2021/PRNewswire/ - Genetron Health (Nasdaq: GTH) today announced that it has entered into a partnership with NeoGenomics, Inc.

Based on this cooperation, the two parties will integrate their respective superior resources, relying on multiple core technology platforms and product pipelines (covering molecular testing, histopathological diagnosis, multiple fluorescent immunohistochemistry, flow cytometry, immunoassay, in situ hybridization and cytogenetic mapping Etc.

Hu Yunfu, Chief Medical Officer of Genetron Health, said: “As an international advanced tumor center laboratory solution provider, Xinjihao has accumulated rich clinical trial experience and capabilities around the world

Dr.

About Xinjihao

Xinjihao (NASDAQ: NEO) is a medical company specializing in cancer genetic testing and information services

Xinjihao is headquartered in Fort Myers, Florida, USA, in Fort Myers and Tampa, Florida, Aliso Viejo, Carlsbad and San Diego, California, and Houston, Texas , Atlanta, Georgia and Nashville, Tennessee have CAP accredited and CLIA accredited laboratories; and CAP accredited laboratories in Rolle, Switzerland and Singapore

About Panshengzi

Generic Health (Nasdaq: GTH) is a global cutting-edge cancer precision medicine company, focusing on cancer genomics research and application, and is committed to changing the way of cancer diagnosis and treatment relying on advanced molecular biology and big data analysis capabilities

Safe Harbor Statement

This press release contains Genetron Health's future expectations, plans and forward-looking statements, which are subject to corresponding risks and uncertainties, which may cause actual results to differ from the expectations described in the forward-looking statements

Source: Genetron Health